BRAXIA SCIENTIFIC CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.005 CAD | 0.00% |
|
0.00% | -50.00% |
| 02-29 | Braxia Scientific Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
| 2023 | Braxia Scientific Corp. Announces Board Changes | CI |
Valuation
| Fiscal Period: March | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 157.8 | 11.91 | 6.593 |
| Enterprise Value (EV) 1 | 146.8 | 3.454 | 5.338 |
| P/E ratio | -1.58 x | -0.87 x | -0.43 x |
| Yield | - | - | - |
| Capitalization / Revenue | 156,478,252 x | 8,011,742 x | 3,499,005 x |
| EV / Revenue | 145,576,075 x | 2,322,657 x | 2,832,851 x |
| EV / EBITDA | -13,926,095 x | -484,853 x | -798,737 x |
| EV / FCF | -111,862,095 x | -1,246,648 x | -1,306,864 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 9.93 x | 1.33 x | 4.11 x |
| Nbr of stocks (in thousands) | 177,290 | 198,579 | 263,709 |
| Reference price 2 | 0.8900 | 0.0600 | 0.0250 |
| Announcement Date | 7/29/21 | 7/29/22 | 7/31/23 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales | - | 1.008 | 1.487 | 1.884 |
| EBITDA | - | -10.54 | -7.124 | -6.683 |
| EBIT 1 | -3.3 | -10.54 | -7.135 | -7.208 |
| Operating Margin | - | -1,045.42% | -479.77% | -382.57% |
| Earnings before Tax (EBT) 1 | -3.3 | -88.45 | -12.18 | -13.29 |
| Net income 1 | -3.3 | -88.83 | -12.13 | -13.14 |
| Net margin | - | -8,809.07% | -815.93% | -697.48% |
| EPS 2 | -212.7 | -0.5635 | -0.0692 | -0.0575 |
| Free Cash Flow | - | -1.312 | -2.771 | -4.084 |
| FCF margin | - | -130.14% | -186.31% | -216.77% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 7/29/21 | 7/29/21 | 7/29/22 | 7/31/23 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | 3 | 11 | 8.46 | 1.26 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | -1.31 | -2.77 | -4.08 |
| ROE (net income / shareholders' equity) | - | -937% | -97.7% | -249% |
| ROA (Net income/ Total Assets) | - | -61.1% | -29.6% | -58.1% |
| Assets 1 | - | 145.3 | 40.99 | 22.63 |
| Book Value Per Share 2 | 192.0 | 0.0900 | 0.0500 | 0.0100 |
| Cash Flow per Share 2 | 197.0 | 0.0600 | 0.0400 | 0.0100 |
| Capex | - | 0.02 | 0.03 | 0.83 |
| Capex / Sales | - | 2.18% | 1.7% | 43.91% |
| Announcement Date | 7/29/21 | 7/29/21 | 7/29/22 | 7/31/23 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -50.00% | 1.04M | |
| +18.41% | 83.07B | |
| -29.08% | 70.89B | |
| +3.59% | 28.32B | |
| -7.08% | 17.73B | |
| +2.07% | 17.43B | |
| +0.93% | 15.64B | |
| +6.78% | 13.46B | |
| +8.40% | 12.82B | |
| +68.45% | 12.69B |
- Stock Market
- Equities
- BRAX Stock
- Financials Braxia Scientific Corp.